Status: Closed

Trial Summary

Pet dogs that are enrolled in the study will receive a single dose of a novel, oral anti-cancer agent. Serial blood samples and lymph node aspirates will then be collected over a 24-hour period.  Patients will return for evaluation 7 days after the single dose of therapy is administered.

For participation, clients will receive $2000 towards oncology care.

Trial Eligibility

• Client-owned pet dogs > 1 year of age, 10-45 kg, with life expectancy of > 1 month;
• Informed owner consent prior to initiation of screening/treatment;
• Histological or cytological diagnosis of non-Hodgkins lymphoma with one or more measurable lymph nodes (Minimum tumor diameter is ≥ 20 mm);
• Stage II to V (only substage a) lymphoma of either B or T cell origin;
• Naïve (i.e. de novo) and relapsed cases;
• Favorable Performance Score;
• Prior treatment with chemotherapy or prednisone therapy is accepted but a 14-day washout is required.

Trial Participation

The following sites are evaluating patients for participation in this clinical trial:

The Oncology Service
Friendship Hospital for Animals
4105 Brandywine St., NW
Washington, DC 20016
(202) 363-7300

Red Bank Veterinary Hospital
197 Hance Ave.
Tinton Falls, NJ 07724
(732) 747-3636

New England Veterinary Oncology Group
180 Bear Hill Rd., Suite C
Waltham, MA 02451
(781) 684-8688